1 2 3 4 5 6 7 8 9 10
читать далее ... tem M Mohr D et al Risk factors for deep vein thrombosis and pulmonary embolism a population-based case-control study Arch Intern Med , 2000 160, 809-815 26 Deitcher S Cancer-related deep venous thrombosis clinical importance, treatment challenges, and management strategies Semin Thromb Hemost, 2003, 29 (3), 247-258 27 Buller H , Agnelh G , Hull R et al Antlthrombotic therapy for venous thromboembollc disease The Seventh ACCP Conference on Antlthrombotic and Thrombolytic Therapy Chest, 2004, 126, 401S-428S 28 Dolovich L , Gmsberg J , Douketis J et al A metaanalysis comparing low-molecular-weight hepanns with unfractionated hepann in the treatment of venous thromboembolism examining some unanswered questions regarding location of treatment, product type, and dosing frequency Arch Intern Med , 2000, 160, 181-188 29 Zacharski L , Prandom P Monreal M Warfarin versus low-molecular-weight hepann therapy in cancer patients Oncologist, 2005, 10 (1), 72-79 30 Lee A , Levme M , Baker R et al Low-molecular-weight hepann versus a coumann for the prevention of recurrent venous thromboembolism in patients with cancer N EngI J Med , 2003, 349, 146-153 31 Hull R , Pmeo G , Mah A et al A randomised tnal evaluating long-term lowmolecular-weight hepann therapy for three months vs intravenous hepann followed by warfarin sodium in patients with current cancer [abstract] Thromb Haemost 2003, (suppi), P137a 32 Kher A , Samama M Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight hepanns prolonged thromboprophylaxis, an alternative to vitamin К antagonists J Thromb Haemost, 2005, 3 (3), 473-481 33 Mousa S Low-molecular-weight hepanns in thrombosis and cancer emerging links Cardiovasc Drug Rev , 2004, 22 (2), 121-134 34 Castelh R , Porro F , Tarsia P The hepanns and cancer review of clinical tnals and biological properties Vase Med , 2004 9 (3), 205-213 35 Mousa S Mohamed S Anti-angiogenic mechanisms and efficacy of the low molecular weight hepann, tmzaparm anti-cancer efficacy Oncol Rep , 2004, 12 (4), 683-688 36 Conti S , Guercmi F lono A Low-molecular-weight hepann and cancer survival review of the literature and pooled analysis of 1,726 patients treated for at least three months Pathophysiol Haemost Thromb 2004, 33 (4), 197-201 37 Klerk С , Smorenburg S , Otten H et al The effect of low molecular weight hepann on survival in patients with advanced malignancy J Clin Oncol, 2005, Feb 7 38 Lee A Rickles F , Julian J et al Randomized comparison of low molecular weight hepann and coumann denvatives on the survival of patients with cancer and venous thromboembolism J Clin Oncol, 2005, Feb 7Источник: Моисеев С.В. и др. Клиническая фармакология и терапия. 2005. №3. С. 27-32